摘要：由国际肺癌研究协会（IASLC）主办的2025年世界肺癌大会（WCLC2025）于2025年9月6-9日在西班牙巴塞罗那召开。作为肺癌及其他胸部恶性肿瘤领域全球领先的多学科肿瘤学盛会，本次大会吸引了来自世界各地的众多专家学者参会，围绕肺癌及其他胸部恶性肿瘤的前

由国际肺癌研究协会（IASLC）主办的2025年世界肺癌大会（WCLC2025）于2025年9月6-9日在西班牙巴塞罗那召开。作为肺癌及其他胸部恶性肿瘤领域全球领先的多学科肿瘤学盛会，本次大会吸引了来自世界各地的众多专家学者参会，围绕肺癌及其他胸部恶性肿瘤的前沿诊疗进展展开了深入探讨。会议现场，《肿瘤瞭望》特邀大会主席、西班牙巴塞罗那医院Noemí Reguart教授接受专访，解读会议议程设置及研究成果相关亮点，特此整理，以飨读者。

专家简介

Noemí Reguart 教授

西班牙巴塞罗那医院胸部肿瘤科主任

巴塞罗那大学医学院副教授

欧洲癌症研究与治疗组织（EORTC）小细胞肺癌小组主席

国际肺癌研究协会（IASLC）通讯委员会成员

西班牙肺癌小组（SLCG）董事会成员

2025 年世界肺癌大会（WCLC）、2025 年 ESMO - ASIA科学委员会胸部肿瘤联合主席分会联合主席

大会联合主席Noemi Reguart教授表示，自己深感荣幸能担任本次大会联合主席之一，而本届大会的核心目标之一，便是汇聚全球同仁，集中展示非小细胞肺癌及其他胸部肿瘤领域的关键进展。

议程设置亮点

谈及本届大会议程设置亮点，Noemi Reguart教授指出两点核心：其一，大会议程紧密围绕双特异性抗体、抗体药物偶联物（ADCs）等创新疗法，同时覆盖肺癌筛查、外科手术等基础研究与临床诊疗核心方向，全面覆盖领域前沿与实践需求；其二，大会特别凸显多学科协作模式的重要性——该模式联动外科医生、放疗科医生、病理科医生及内科肿瘤医生，对早期肺癌患者的规范化管理与治疗（包括诱导治疗、手术及辅助治疗）起到关键支撑作用。

谈及与去年大会的差异，Noemi Reguart教授提到，今年参会规模实现增长，参会代表达7500余人；从会议意义看，去年大会聚焦IASLC胸部肿瘤学领域50周年发展成果纪念，今年则正式开启未来50年全球携手抗击胸部肿瘤的新征程，两届大会内容均具高度学术价值。此外，本届大会对她而言更具特殊意义——会议举办地巴塞罗那，正是她出生与工作的城市。

入选研究亮点

关于大会研究成果的核心重点，Noemi Reguart教授介绍，今年大会呈现了多场高质量全体大会报告，内容既聚焦各阶段临床试验进展，也包含众多优质基础研究及筛查研究的成果分享。她强调，这些试验虽暂未达到改变临床实践的程度，但为领域发展提供了关键洞见与数据支撑，明确了后续研究方向；而本届大会对研究的筛选，均以填补当前认知空白为核心目标，为推动肺癌领域临床转化提供必要信息。

Prof. Noemi Reguart：Hello, everyone. We are here at the 2025 World Conference on Lung Cancer (WCLC) in my hometown, Barcelona. I am deeply honored to have the opportunity to serve as one of the co-chairs of this conference. A core objective of this year’s event is to bring together colleagues from around the world to focus on presenting the key advances in non-small cell lung cancer and other thoracic tumors.

As you can see, the people behind me, we are show casing data related to the most novel therapies and therapeutic approaches. When it comes to the highlights of the conference agenda, there are two core aspects to emphasize. First, the agenda is closely centered on innovative therapies such as bispecifics and Antibody-Drug Conjugates (ADCs), while also covering core directions in basic research and clinical practice including lung cancer screening and surgical procedures, fully addressing both cutting-edge developments and practical needs in the field. Second, the conference places special emphasis on the importance of the multidisciplinary approach, which unites surgeons, radiation oncologists, pathologists, and medical oncologists. This approach plays a crucial supporting role in the standardized management and treatment of patients with early-stage lung cancer, including induction therapy, surgery, and adjuvant therapy, it is something we must work on together. For all these reasons, I am truly honored to be a co-chair of this conference.

Well, compared to last year's WCLC, one notable difference is the scale of attendance—this year, we have over 7,500 delegates, which is an increase from last year. In terms of the conference’s significance, last year’s event focused on commemorating the 50th anniversary of progress in thoracic oncology, while this year we are officially launching the next 50-year journey of global collaboration to combat thoracic cancers. Both conferences have maintained high academic value in their content.Moreover, this year, the conference has featured multiple high-quality plenary sessions. The content not only focuses on progress in clinical trials across all phases but also includes the sharing of results from numerous high-quality academic trials and screening trials. I want to emphasize that while these trials have not yet reached the level of changing clinical practice, they have provided critical insights and data support for the development of the field, and clarified the direction of future research.And the selection of trials for this year’s conference is centered on a core goal: filling gaps in our current knowledge. This is aimed at providing the necessary information to advance clinical translation in the field of lung cancer.

来源：肿瘤瞭望